These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 15897947)

  • 1. Positron emission tomography and single-photon emission computed tomography in central nervous system drug development.
    Brooks DJ
    NeuroRx; 2005 Apr; 2(2):226-36. PubMed ID: 15897947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarkers in Randomized Clinical Trials: Positron Emission Tomography and Nuclear Medicine Techniques.
    Singhal T; Stern E
    Front Neurol Neurosci; 2016; 39():109-16. PubMed ID: 27463807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiopharmaceuticals in neurological and psychiatric disorders.
    Valotassiou V; Wozniak G; Sifakis N; Demakopoulos N; Georgoulias P
    Curr Clin Pharmacol; 2008 May; 3(2):99-107. PubMed ID: 18690884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PET and SPECT imaging of the NMDA receptor system: an overview of radiotracer development.
    Sobrio F; Gilbert G; Perrio C; Barré L; Debruyne D
    Mini Rev Med Chem; 2010 Aug; 10(9):870-86. PubMed ID: 20504276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Receptor Occupancy Imaging Studies in Oncology Drug Development.
    Burvenich IJG; Parakh S; Parslow AC; Lee ST; Gan HK; Scott AM
    AAPS J; 2018 Mar; 20(2):43. PubMed ID: 29520671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular imaging with SPECT as a tool for drug development.
    Gomes CM; Abrunhosa AJ; Ramos P; Pauwels EK
    Adv Drug Deliv Rev; 2011 Jun; 63(7):547-54. PubMed ID: 20933557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging studies in drug development: Parkinson's disease.
    Brooks DJ
    Drug Discov Today Technol; 2005; 2(4):317-21. PubMed ID: 24982007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PET and SPECT tracers for glutamate receptors.
    Majo VJ; Prabhakaran J; Mann JJ; Kumar JS
    Drug Discov Today; 2013 Feb; 18(3-4):173-84. PubMed ID: 23092894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Translational PET imaging research.
    Hargreaves RJ; Rabiner EA
    Neurobiol Dis; 2014 Jan; 61():32-8. PubMed ID: 24055214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic review of molecular imaging (PET and SPECT) in autism spectrum disorder: current state and future research opportunities.
    Zürcher NR; Bhanot A; McDougle CJ; Hooker JM
    Neurosci Biobehav Rev; 2015 May; 52():56-73. PubMed ID: 25684726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological challenge and synaptic response - assessing dopaminergic function in the rat striatum with small animal single-photon emission computed tomography (SPECT) and positron emission tomography (PET).
    Nikolaus S; Larisch R; Vosberg H; Beu M; Wirrwar A; Antke C; Kley K; Silva MA; Huston JP; Müller HW
    Rev Neurosci; 2011; 22(6):625-45. PubMed ID: 22103308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of brain imaging instrumentation.
    Abraham T; Feng J
    Semin Nucl Med; 2011 May; 41(3):202-19. PubMed ID: 21440696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Miscellaneous cancers (lung, thyroid, renal cancer, myeloma, and neuroendocrine tumors): role of SPECT and PET in imaging bone metastases.
    Chua S; Gnanasegaran G; Cook GJ
    Semin Nucl Med; 2009 Nov; 39(6):416-30. PubMed ID: 19801221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET measurement of receptor occupancy as a tool to guide dose selection in neuropharmacology: are we asking the right questions?
    Barrett JS; McGuire J; Vezina H; Spitsin S; Douglas SD
    J Clin Psychopharmacol; 2013 Dec; 33(6):725-8. PubMed ID: 24100788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical evaluation of CNS drugs with PET].
    Takano A
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2009 Apr; 29(2):61-5. PubMed ID: 19562943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of PET and SPECT probes for glutamate receptors.
    Fuchigami T; Nakayama M; Yoshida S
    ScientificWorldJournal; 2015; 2015():716514. PubMed ID: 25874256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Large Variation in Brain Exposure of Reference CNS Drugs: a PET Study in Nonhuman Primates.
    Schou M; Varnäs K; Lundquist S; Nakao R; Amini N; Takano A; Finnema SJ; Halldin C; Farde L
    Int J Neuropsychopharmacol; 2015 Mar; 18(10):pyv036. PubMed ID: 25813017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nuclear imaging of inflammation in neurologic and psychiatric disorders.
    de Vries EF; Dierckx RA; Klein HC
    Curr Clin Pharmacol; 2006 Sep; 1(3):229-42. PubMed ID: 18666748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Analysis of the drawbacks of single photon emission computed tomography and positron emission tomography imaging].
    Mizumura S
    Brain Nerve; 2010 May; 62(5):489-500. PubMed ID: 20450096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positron emitting tracers in pre-clinical drug development.
    Fernandes E; Barbosa Z; Clemente G; Alves F; Abrunhosa AJ
    Curr Radiopharm; 2012 Apr; 5(2):90-8. PubMed ID: 22280107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.